Xiamen Amoytop Biotech Third Quarter 2024 Earnings: EPS: CN¥0.61 (vs CN¥0.41 in 3Q 2023)

Simply Wall St · 10/26 00:09

Xiamen Amoytop Biotech (SHSE:688278) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥764.9m (up 38% from 3Q 2023).
  • Net income: CN¥249.8m (up 50% from 3Q 2023).
  • Profit margin: 33% (up from 30% in 3Q 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.61 (up from CN¥0.41 in 3Q 2023).
earnings-and-revenue-growth
SHSE:688278 Earnings and Revenue Growth October 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xiamen Amoytop Biotech Earnings Insights

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Xiamen Amoytop Biotech that you should be aware of.